MedPath

Primitive Immunodeficiency and Pregnancy

Completed
Conditions
Primary Immune Deficiency
Interventions
Other: Questionnaire
Registration Number
NCT04581460
Lead Sponsor
Assistance Publique - H么pitaux de Paris
Brief Summary

The management of patients with primary immune deficiency is increasingly codified, however contraception and pregnancy have not yet extensively studied or codified, and the medical monitoring and the prevention of infectious complications thus remains at the discretion of the practitioner.

The aim the research is to study the obstetric features and outcome of patients with primary immune defects.

Detailed Description

Primary immune deficiencies constitute a large group of immune system disorders of genetic origin which can associate, to varying degrees, an increased susceptibility to infections and immunopathological manifestations: allergy, inflammation, autoimmunity, lymphoproliferation, tumors malignant.

Although their prevalence remains underestimated, there has been an increase in the number of cases diagnosed in the past 10 years. The national average prevalence is 8.6 patients per 100,000 inhabitants and the diagnostic incidence is 400 new cases per year in France. Major improvement in the management of primary immunodeficiencies have drastically changed patients outcome. Most patients now reach adulthood and the possibility of carrying out a pregnancy project, that has already reported for patients suffering from hypogammaglobulinemia or variable common immune deficiency, is now increasingly reported for other types of inherited immunodeficiencies. Whereas the management of patients with hereditary immunodeficiencies is increasingly codified, contraception and pregnancy have not yet been the subject of recommendations: medical monitoring and the prevention of infectious complications thus remain at the discretion of the practitioner.

The aim the research is to study the obstetric experiences of patients with a primary immune deficiency, paying particular attention to infectious complications.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
99
Inclusion Criteria
  • Adult woman with Hereditary Immune Deficits and entered in the reference Center for Hereditary Immune Deficits (CEREDIH, hospital Necker-Enfants Malades, Paris) register
  • Patient having reported at least one pregnancy or attempted pregnancy
  • Patient not opposing to participation in research
Exclusion Criteria
  • Refusal to participate of the study

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
PatientsQuestionnairePatients entered in the register of the reference Center for Hereditary Immune Deficits (CEREDIH), hospital Necker-Enfants Malades, Paris, and having reported at least one pregnancy or attempted pregnancy
Primary Outcome Measures
NameTimeMethod
Infectious events18 months

Number of infectious events at any time during pregnancy and post-partum

Secondary Outcome Measures
NameTimeMethod
Pregnancy outcomesUp to 9 months

Rate of early or late miscarriage, completed pregnancy, live birth and childbearing

Occurrence of obstetric complications9 months

Rate of obstetric complications

Contraception effectivenessUp to 50 years

Number of unwanted pregnancies

Contraception complicationsUp to 50 years

Number of non-infectious complications of contraception

Deaths and complications in the neonatal period3 months

Number of complications during neonatal period, including death

Onset of pregnancyUp to 50 years

Number of pregnancies during reproductive age period

Screening of infections9 months

Presence/absence of screening for infections

Infectious gynecological complicationsUp to 50 years

Number of infectious gynecological complications during contraception

Treatments9 months

Number of treatments aiming at preventing infections

Trial Locations

Locations (1)

H么pital Necker-Enfants Malades

馃嚝馃嚪

Paris, France

漏 Copyright 2025. All Rights Reserved by MedPath